NCT07029555 is a Phase 1 clinical trial of PIT565 in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT07029555?

NCT07029555 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT07029555?

Interventions in NCT07029555: PIT565.

What condition does NCT07029555 study?

NCT07029555 studies Rheumatoid Arthritis.

Is NCT07029555 still recruiting?

NCT07029555 is currently recruiting now. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT07029555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

Recruiting now Phase 1 Last updated 23 March 2026

What this trial tests

Phase 1 trial testing PIT565 in Rheumatoid Arthritis in 57 participants. Currently enrolling.

Timeline

12 June 2025

Primary endpoint
15 May 2028

16 May 2028

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	12 June 2025
Primary completion	15 May 2028
Estimated completion	16 May 2028
Sites	13 locations across France, Netherlands, Germany, Hungary, Argentina, Romania, Bulgaria, China

Drugs / interventions tested

PIT565 — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 75, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PIT565

Trials testing the same drug.

NCT06335979 — An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). · Phase 1 · recruiting
NCT05397496 — Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies · Phase 1 · active not recruiting

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07029555 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07029555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing